Clinical Heterogeneity Associated with MYO7A Variants Relies on Affected Domains. [PDF]
Biomedicines, 2022 Joo SY +11 more
europepmc +1 more source
Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. [PDF]
Haematologica, 2017 Wang J +8 more
europepmc +1 more source
The Impact of Angiogenesis in the Most Common Salivary Gland Malignant Tumors. [PDF]
Int J Mol Sci, 2020 Pouloudi D +6 more
europepmc +1 more source
PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase. [PDF]
PLoS One, 2017 Alonso-Dominguez JM +18 more
europepmc +1 more source
Targeted disruption of the BCR-ABL fusion gene by Cas9/dual-sgRNA inhibits proliferation and induces apoptosis in chronic myeloid leukemia cells. [PDF]
Acta Biochim Biophys Sin (Shanghai)Zeng J +9 more
europepmc +1 more source
Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival. [PDF]
J Proteome Res, 2019 Noel BM +10 more
europepmc +1 more source
Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo. [PDF]
Ann Hematol, 2019 Jyotsana N +19 more
europepmc +1 more source
Hydrogen Sulfide Biology and Its Role in Cancer. [PDF]
Molecules, 2022 Khattak S +11 more
europepmc +1 more source
Usher syndrome and Nebulin-associated myopathy in a single patient due to variants in MYO7A and NEB. [PDF]
Clin Case Rep, 2020 Maia N +8 more
europepmc +1 more source
In the absence of frazzled over-expression of Abelson tyrosine kinase disrupts commissure formation and causes axons to leave the embryonic CNS. [PDF]
PLoS One, 2010 Dorsten JN +4 more
europepmc +1 more source